Earnings Report: Amylin Pharmaceuticals Reported Mixed Q1 Results, Top Line Down 3.3% (AMLN)

Amylin Pharmaceuticals (NASDAQ:AMLN) reported a fiscal Q1 loss of $0.27 per share, ahead of consensus estimates for a loss of $0.29 per share.

Revenues fell 3.3% to $174.1 million, missing consensus estimates of $187.8 million.

President and CEO Daniel M. Bradbury said, "With the submission of our BYDUREON response this week, we are preparing to make this revolutionary treatment option available this year to the millions of patients living with type 2 diabetes. We remain focused on driving revenue from our currently marketed products, BYETTA and SYMLIN, and continue to exercise financial discipline so that we remain on track to generate sustainable positive operating cash flow by year end."

Category:

News & Politics

Tags:

• Amylin
• Pharmaceuticals
• AMLN
• Stock
• News
• Earnings